Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group

Ying Ying Leung; D. William Tillett; Maarten de Wit; C. Ana Maria Orbai; Laura C. Coates; Oliver FitzGerald; Philip S. Helliwell; Vibeke Strand; Philip J. Mease; Niti Goel; Robin Christensen; Joseph F. Merola; Christine A. Lindsay; B. Alexis Ogdie; Laure Gossec; Dafna D. Gladman

doi:10.3899/JRHEUM.2023-0530

Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group

Ying Ying Leung, D. William Tillett, Maarten de Wit, C. Ana Maria Orbai, Laura C. Coates, Oliver FitzGerald, Philip S. Helliwell, Vibeke Strand, Philip J. Mease, Niti Goel, Robin Christensen, Joseph F. Merola, Christine A. Lindsay, B. Alexis Ogdie, Laure Gossec, Dafna D. Gladman

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) working group-comprising rheumatologists, dermatologists, methodologists, and patient research partners-provided updates at the GRAPPA 2022 annual meeting on its work to evaluate composite outcome measures for PsA. Ten composite outcome measures were considered. Initial steps were to define the population, the purpose of use, and the proposed pros and cons of the 10 candidate composite instruments for PsA. Preliminary Delphi exercises within the working group and GRAPPA stakeholders confirmed high priority for evaluating minimal disease activity (AIDA); moderate priority for Disease Activity in PsA (DAPSA), American College of Rheumatology (ACR) response criteria, Psoriatic Arthritis Disease Activity Score (PASDAS), Composite Psoriatic Disease Activity Index (CPDAI), 3 visual analog scale (VAS), and 4VAS; and low priority for Disease Activity Score in 28 joints (DAS28), Psoriatic Arthritis Responder Criteria (PsARC), and Routine Assessment of Patient Index Data 3 (RAPID 3). Further appraisal of candidate composite instruments is ongoing.

Original language	English (US)
Pages (from-to)	53-57
Number of pages	5
Journal	Journal of Rheumatology
Volume	50
DOIs	https://doi.org/10.3899/JRHEUM.2023-0530
State	Published - Nov 1 2023

Keywords

GRAPPA
composite outcome measures
outcome measures
physical function
psoriasis
psoriatic arthritis

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy
Immunology

Access to Document

10.3899/JRHEUM.2023-0530

Cite this

Leung, Y. Y., Tillett, D. W., de Wit, M., Orbai, C. A. M., Coates, L. C., FitzGerald, O., Helliwell, P. S., Strand, V., Mease, P. J., Goel, N., Christensen, R., Merola, J. F., Lindsay, C. A., Ogdie, B. A., Gossec, L., & Gladman, D. D. (2023). Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group. Journal of Rheumatology, 50, 53-57. https://doi.org/10.3899/JRHEUM.2023-0530

Leung, YY, Tillett, DW, de Wit, M, Orbai, CAM, Coates, LC, FitzGerald, O, Helliwell, PS, Strand, V, Mease, PJ, Goel, N, Christensen, R, Merola, JF, Lindsay, CA, Ogdie, BA, Gossec, L & Gladman, DD 2023, 'Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group', Journal of Rheumatology, vol. 50, pp. 53-57. https://doi.org/10.3899/JRHEUM.2023-0530

@article{89abd201b4fd4fd3b2a6d374f76a1818,

title = "Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group",

abstract = "The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) working group-comprising rheumatologists, dermatologists, methodologists, and patient research partners-provided updates at the GRAPPA 2022 annual meeting on its work to evaluate composite outcome measures for PsA. Ten composite outcome measures were considered. Initial steps were to define the population, the purpose of use, and the proposed pros and cons of the 10 candidate composite instruments for PsA. Preliminary Delphi exercises within the working group and GRAPPA stakeholders confirmed high priority for evaluating minimal disease activity (AIDA); moderate priority for Disease Activity in PsA (DAPSA), American College of Rheumatology (ACR) response criteria, Psoriatic Arthritis Disease Activity Score (PASDAS), Composite Psoriatic Disease Activity Index (CPDAI), 3 visual analog scale (VAS), and 4VAS; and low priority for Disease Activity Score in 28 joints (DAS28), Psoriatic Arthritis Responder Criteria (PsARC), and Routine Assessment of Patient Index Data 3 (RAPID 3). Further appraisal of candidate composite instruments is ongoing.",

keywords = "GRAPPA, composite outcome measures, outcome measures, physical function, psoriasis, psoriatic arthritis",

author = "Leung, {Ying Ying} and Tillett, {D. William} and {de Wit}, Maarten and Orbai, {C. Ana Maria} and Coates, {Laura C.} and Oliver FitzGerald and Helliwell, {Philip S.} and Vibeke Strand and Mease, {Philip J.} and Niti Goel and Robin Christensen and Merola, {Joseph F.} and Lindsay, {Christine A.} and Ogdie, {B. Alexis} and Laure Gossec and Gladman, {Dafna D.}",

note = "Publisher Copyright: {\textcopyright} 2023 The Journal of Rheumatology.",

year = "2023",

month = nov,

day = "1",

doi = "10.3899/JRHEUM.2023-0530",

language = "English (US)",

volume = "50",

pages = "53--57",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

}

TY - JOUR

T1 - Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis

T2 - 2022 Updates From the GRAPPA-OMERACT Working Group

AU - Leung, Ying Ying

AU - Tillett, D. William

AU - de Wit, Maarten

AU - Orbai, C. Ana Maria

AU - Coates, Laura C.

AU - FitzGerald, Oliver

AU - Helliwell, Philip S.

AU - Strand, Vibeke

AU - Mease, Philip J.

AU - Goel, Niti

AU - Christensen, Robin

AU - Merola, Joseph F.

AU - Lindsay, Christine A.

AU - Ogdie, B. Alexis

AU - Gossec, Laure

AU - Gladman, Dafna D.

PY - 2023/11/1

Y1 - 2023/11/1

N2 - The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) working group-comprising rheumatologists, dermatologists, methodologists, and patient research partners-provided updates at the GRAPPA 2022 annual meeting on its work to evaluate composite outcome measures for PsA. Ten composite outcome measures were considered. Initial steps were to define the population, the purpose of use, and the proposed pros and cons of the 10 candidate composite instruments for PsA. Preliminary Delphi exercises within the working group and GRAPPA stakeholders confirmed high priority for evaluating minimal disease activity (AIDA); moderate priority for Disease Activity in PsA (DAPSA), American College of Rheumatology (ACR) response criteria, Psoriatic Arthritis Disease Activity Score (PASDAS), Composite Psoriatic Disease Activity Index (CPDAI), 3 visual analog scale (VAS), and 4VAS; and low priority for Disease Activity Score in 28 joints (DAS28), Psoriatic Arthritis Responder Criteria (PsARC), and Routine Assessment of Patient Index Data 3 (RAPID 3). Further appraisal of candidate composite instruments is ongoing.

AB - The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) working group-comprising rheumatologists, dermatologists, methodologists, and patient research partners-provided updates at the GRAPPA 2022 annual meeting on its work to evaluate composite outcome measures for PsA. Ten composite outcome measures were considered. Initial steps were to define the population, the purpose of use, and the proposed pros and cons of the 10 candidate composite instruments for PsA. Preliminary Delphi exercises within the working group and GRAPPA stakeholders confirmed high priority for evaluating minimal disease activity (AIDA); moderate priority for Disease Activity in PsA (DAPSA), American College of Rheumatology (ACR) response criteria, Psoriatic Arthritis Disease Activity Score (PASDAS), Composite Psoriatic Disease Activity Index (CPDAI), 3 visual analog scale (VAS), and 4VAS; and low priority for Disease Activity Score in 28 joints (DAS28), Psoriatic Arthritis Responder Criteria (PsARC), and Routine Assessment of Patient Index Data 3 (RAPID 3). Further appraisal of candidate composite instruments is ongoing.

KW - GRAPPA

KW - composite outcome measures

KW - outcome measures

KW - physical function

KW - psoriasis

KW - psoriatic arthritis

UR - http://www.scopus.com/inward/record.url?scp=85176496334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85176496334&partnerID=8YFLogxK

U2 - 10.3899/JRHEUM.2023-0530

DO - 10.3899/JRHEUM.2023-0530

M3 - Article

C2 - 37419621

AN - SCOPUS:85176496334

SN - 0315-162X

VL - 50

SP - 53

EP - 57

JO - Journal of Rheumatology

JF - Journal of Rheumatology

ER -

Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this